anti-VEGF treatment
PreclinicalSmall molecule
Bayeranti-VEGF treatment is one of 86 small molecule programs targeting Intelligence. It is currently in Preclinical.
5
Indications
5
Total Trials
2
Active Trials
85
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
43 competitors in Age-Related Macular Degeneration
#DrugCompanyPhaseTrials
1Eylea
RegeneronApproved
Zometa
PfizerApproved
Plavix
SanofiApproved
Bayer Aspirin
BayerApproved
Tecfidera
BiogenApproved
Visudyne
BBausch Health Americas, Inc.
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Bendopa
MMerz North America, Inc.
Approved
Lodosyn
LLaTonya J. Hickson
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Wet Age-Related Macular Degeneration1 trial
Age-Related Macular Degeneration1 trial
Effect of Micronutrient Supplementation on the Intestinal Microbiota in Patients With Age-related Macular Degeneration - The Gut-Retina-axis Study
Completed·—·N/A·NCT06391411·45 enrolled
Dexamethasone1 trial
Intelligence1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for anti-VEGF treatment. EMBL-EBI & Wellcome Sanger Institute.
- [4]